Shamburg News · 8-K filed Nov 13, 2026, 4:30 PM EST
IRulya Therapeutics Reports Third Quarter 2026 Net Loss of $27.7 Million
IRLA · IRulya Therapeutics Inc.
- Earnings
- Materiality: high
IRulya Therapeutics Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $27.7 million, or $2.31 per basic and diluted share, compared with a net loss of $13.4 million, or $49.83 per share, a year earlier. R&D expense was $5.9 million and G&A expense was $9.0 million for the quarter. Cash, cash equivalents and investments were $105.2 million as of September 30, 2026, which the company expects to fund operations through the end of 2028.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-460775.
Written from the filing by Shamburg Markets. Figures are as reported by the company.